Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 3 Study Dexpramipexole (KNS-760704) Treatment Report
What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?

NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 34 23 Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Participate in clinical trial 12 5 Efficacy_moderate Efficacy_none Efficacy_cant_tell
Increase effect of another treatment 2 0

See all 44 patients currently using ALS Phase 3 Study Dexpramipexole (KNS-760704)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 2
Mild
 5
None
 17

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 3 Study Dexpramipexole (KNS-760704)

Nausea 3
Insomnia 2
Neutropenia (low neutrophils) 2
Hospitalization 2
Difficulty sleeping through night 1
Oily skin (ie forehead nose ears) 1
See all 14 reported side effects ▼ See top 6 reported side effects ▲

Reported Schedules

  2 mg daily 2 intl units daily 2 daily 2 other daily 30 mg daily 150 mg daily 300 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 10 Number of Patients: 10 5 Number of Patients: 5 1 Number of Patients: 1 1 Number of Patients: 1 26 Number of Patients: 26  

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 3 Study Dexpramipexole (KNS-760704) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 4   Other: 100%
Side effects too severe 2   Side effects too severe: 50%
Personal research 1   Personal research: 25%

See all 4 patients who’ve stopped using ALS Phase 3 Study Dexpramipexole (KNS-760704)

Reported Duration See details about how long patients take this treatment ▼

Currently Using ALS Phase 3 Study Dexpramipexole (KNS-760704)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Using ALS Phase 3 Study Dexpramipexole (KNS-760704)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 3 Study Dexpramipexole (KNS-760704)

Always
 22 88%
Usually
 2 8%
Sometimes
 0 0%
Never
 1 4%

Burden

Difficulty being on treatment

Burden of ALS Phase 3 Study Dexpramipexole (KNS-760704)

Very
 0 0%
Somewhat
 0 0%
A little
 4 16%
Not at all
 21 84%

Cost

Paid out of pocket

Cost of ALS Phase 3 Study Dexpramipexole (KNS-760704)

$200+
 0 0%
$100-199
 1 5%
$50-99
 1 5%
$25-49
 0 0%
< $25
 20 91%

Report created on May 28, 2012.